Today BTIG Research Reconfirms a Buy Rating on Eiger BioPharmaceuticals (EIGR) and a $39 Target Price

May 17, 2018 - By Ash Ash

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger BioPharmaceuticals (EIGR) Rating Reaffirmed

In a research note sent to investors and clients on Thursday morning, The Buy rating of Eiger BioPharmaceuticals (EIGR) shares was reiterated by BTIG Research, who now has a $39 PT on the stock. BTIG Research’s PT suggests a possible upside of 132.14 % from the current stock price of the company.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Coverage

Among 5 analysts covering Eiger Biopharmaceuticals (EIGR), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eiger Biopharmaceuticals has $3600 highest and $17.0 lowest target. $25.80’s average target is 53.57% above currents $16.8 stock price. Eiger Biopharmaceuticals had 11 analyst reports since December 19, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, January 16 by Piper Jaffray. Wedbush maintained the shares of EIGR in report on Friday, January 5 with “Buy” rating. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) earned “Buy” rating by Oppenheimer on Wednesday, March 21. On Wednesday, March 21 the stock rating was maintained by Piper Jaffray with “Buy”. The firm has “Buy” rating by Oppenheimer given on Monday, March 12. The firm has “Buy” rating given on Tuesday, December 19 by Wedbush. Jefferies maintained Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) rating on Tuesday, January 16. Jefferies has “Buy” rating and $26.0 target. The rating was maintained by Wedbush with “Buy” on Wednesday, April 18. FBR Capital maintained Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) on Monday, May 14 with “Buy” rating. The stock has “Buy” rating by Oppenheimer on Friday, May 11.

The stock increased 41.77% or $4.95 during the last trading session, reaching $16.8. About 1.29 million shares traded or 1602.10% up from the average. Eiger BioPharmaceuticals, Inc. (EIGR) has declined 11.57% since May 18, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.98 earnings per share, up 26.32 % or $0.35 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $177.07 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For May 9, 2018” on May 09, 2018. Also 247Wallst.com published the news titled: “Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 …” on May 17, 2018. Streetinsider.com‘s news article titled: “After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more…)” with publication date: May 17, 2018 was also an interesting one.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: